Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for ventricular arrhythmias in heart failure patients with ICDs
IRCT20120520009801N7Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and ventricular arrhythmia (VA) comparing Empagliflozin add-on with Placebo add-on (2 arms). Primary endpoint: Frequency of ventricular arrhythmias. Started Aug 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)ventricular arrhythmia (VA)
Beyond the preview
Go deeper on IRCT20120520009801N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120520009801N7.